Premium Nahrungsergänzungsmittel | artgerecht

Dendritic Cell Vaccine – Explanation & Use

Dendritic cell vaccines are personalized cancer immunotherapies that train the immune system to recognize and attack tumor cells. They represent a promising advance in oncology.

Regular tips about health Regular tips about health

Things worth knowing about "Dendritic cell vaccine"

Dendritic cell vaccines are personalized cancer immunotherapies that train the immune system to recognize and attack tumor cells. They represent a promising advance in oncology.

What Are Dendritic Cell Vaccines?

Dendritic cell vaccines are a form of personalized cancer immunotherapy. They are based on dendritic cells, which are specialized immune cells that act as the command center of the immune system. Dendritic cells capture foreign or abnormal structures (antigens), process them, and present them to T-lymphocytes to initiate a targeted immune response.

In dendritic cell vaccine therapy, dendritic cells are isolated from the patient, loaded with tumor-specific antigens in the laboratory, and then reinjected into the patient. The goal is to stimulate the immune system to recognize and destroy cancer cells specifically.

Mechanism of Action

The mechanism of action of dendritic cell vaccines follows the natural principles of immune activation:

Cell collection: Monocytes (precursor cells) or dendritic cells are isolated from the patient via a process called leukapheresis.
Ex vivo maturation: In the laboratory, the cells are matured and loaded with tumor antigens – proteins characteristic of cancer cells.
Reinfusion: The activated dendritic cells are returned to the patient, typically via subcutaneous injection or direct injection into a lymph node.
Immune activation: Inside the body, these cells present tumor antigens to cytotoxic T-cells, triggering a targeted immune response against the tumor.

The aim is to sensitize the immune system to tumor cells on a lasting basis, enabling cancer cells to be recognized and eliminated without damaging healthy tissue.

Indications and Clinical Use

Dendritic cell vaccines are primarily used or investigated in the treatment of various cancers, including:

Prostate cancer (Sipuleucel-T is the most well-known approved product)
Melanoma (skin cancer)
Glioblastoma (brain tumor)
Renal cell carcinoma
Leukemias and lymphomas

The only dendritic cell vaccine currently approved by the U.S. Food and Drug Administration (FDA) is Sipuleucel-T (Provenge®), indicated for castration-resistant prostate cancer.

Treatment Process

The production of a dendritic cell vaccine is a complex, individualized process:

Leukapheresis: White blood cells are collected from the patient.
Cell culture: Monocytes are differentiated into dendritic cells and loaded with tumor antigens in the laboratory.
Quality control: The finished vaccine cells are tested for purity and function.
Administration: The activated cells are given back to the patient in multiple sessions (e.g., three infusions approximately two weeks apart).

Benefits and Potential

Dendritic cell vaccines offer several potential advantages compared to conventional cancer therapies:

High specificity: The therapy targets tumor cells while sparing healthy tissue.
Favorable tolerability: Side effects are generally mild compared to chemotherapy or radiation.
Immune memory: A successful immune response may provide long-term protection against tumor recurrence.
Combination potential: Can be combined with other immunotherapies such as immune checkpoint inhibitors.

Side Effects and Risks

Dendritic cell vaccines are generally well tolerated. Possible side effects include:

Local reactions at the injection site (redness, swelling)
Fatigue
Flu-like symptoms (fever, chills)
Rarely: systemic immune reactions

Serious side effects are uncommon. Since the vaccine is produced from the patient's own cells, the risk of rejection reactions is very low.

Current State of Research

Although Sipuleucel-T remains the only approved product of its kind, numerous clinical trials investigating dendritic cell vaccines for various tumor types are ongoing worldwide. A key focus is the combination with immune checkpoint inhibitors (e.g., PD-1/PD-L1 blockers) to enhance therapeutic efficacy. The use of tumor-specific neoantigens – unique mutations present in an individual patient's tumor – as antigen loading targets is also being intensively explored.

References

Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38-48. doi:10.1016/j.immuni.2013.07.004
Kantoff PW et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine. 2010;363(5):411-422.
National Cancer Institute (NCI). Cancer Vaccines. U.S. National Institutes of Health. Available at: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/vaccines

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.